Cheviot Value Management’s Ligand Pharmaceuticals LGND Stock Holding History

Cheviot Value Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63.2K	Hold	200	–	–	0.01%	194
2026 Q1	$39.9K	Hold	200	–	–	﹤0.01%	209
2025 Q4	$38K	Hold	200	–	–	﹤0.01%	213
2025 Q3	$37.8K	Hold	200	–	–	﹤0.01%	225
2025 Q2	$30K	Hold	200	–	–	﹤0.01%	216
2025 Q1	$21.3K	Buy	+200	New	+$22.6K	﹤0.01%	236

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cheviot Value Management's LGND Position: Q2 2026 in Review

Cheviot Value Management held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 200 shares worth $63.2K. The position accounts for 0.01% of the portfolio, ranked #194.

Cheviot Value Management first reported a position in LGND in Q1 2025 and has held it in 6 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Cheviot Value Management held 200 shares of Ligand Pharmaceuticals worth $63.2K as of Q2 2026.
Cheviot Value Management left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
Ligand Pharmaceuticals made up 0.01% of Cheviot Value Management's portfolio in Q2 2026, its #194 holding.
Cheviot Value Management first reported a position in Ligand Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Cheviot Value Management's 13F filing for Q2 2026, filed 6 Aug 2026.